Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials

Background: Tapinarof cream 1% once daily (QD) demonstrated significant efficacy in patients down to age 2 years with atopic dermatitis (AD) in the ADORING 1 and 2 phase 3 trials. We report local tolerability outcomes.Methods: Patients received Tapinarof or vehicle cream QD for 8 weeks. Tolerability...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Linda Stein Gold, James Del Rosso, Benjamin D. Ehst, Matthew J. Zirwas, Lawrence J. Green, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Anna M. Tallman
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Taylor & Francis Group 2025-12-01
سلاسل:	Journal of Dermatological Treatment
الموضوعات:	Tapinarof cream 1% once daily aryl hydrocarbon receptor agonist atopic dermatitis phase 3 trials adults and children local tolerability scale
الوصول للمادة أونلاين:	https://www.tandfonline.com/doi/10.1080/09546634.2024.2444489
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!